In his session at CROI 2019, Jay Gobler from Merck & Co presented the preliminary data from his phase 2 clinical trial of MK-8591 for the treatment of HIV-1 infection.
In his session at CROI 2019, Jay Gobler from Merck & Co presented the preliminary data from his phase 2 clinical trial of MK-8591 for the treatment of HIV-1 infection.
While neurocognition can increasingly decline with age among individuals with HIV, researchers of a study presented at CROI 2019 determined which factors are connected with neurocognitive decline in the...
By analyzing the association between baseline 10-year cardiovascular risk scores and NPZ-4, researchers determined whether 2 common CVD risk scores could predict later cognitive function. The findings were...
By analyzing the association between baseline 10-year cardiovascular risk scores and NPZ-4, researchers determined whether 2 common CVD risk scores could predict later cognitive function. The findings were...
A new study presented at CROI 2019 explored whether switching to monthly long-acting CAB+RPV is noninferior to continuing current 3-drug oral ART in adults with virologically suppressed HIV-1 infection. ...
A new study presented at CROI 2019 explored whether switching to monthly long-acting CAB+RPV is noninferior to continuing current 3-drug oral ART in adults with virologically suppressed HIV-1 infection. ...
Certain biomarkers could be used to identify people living with HIV who are at increased risk of developing non-alcoholic fatty liver disease, according to recent research.
Alveolar macrophages play an important role in host defense against pathogenic microorganisms and tissue remodeling. In their study, Dr Charles P. Neff and colleagues investigated the effect of HIV and...
